World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
40
Citations
8131
World Ranking
5490
National Ranking
2072

Charles B. Hicks publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Charles B. Hicks sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 279 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Charles B. Hicks D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Charles B. Hicks sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 40 D-Index — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Charles B. Hicks is affiliated with the University of California, San Diego in the United States. Their research primarily focuses on medicine, with notable contributions in immunology and microbiology. Within these fields, their work spans subfields such as infectious diseases, virology, emergency medicine, epidemiology, and immunology.

The scientist's main research topics include HIV research and treatment, HIV-related health complications and treatments, and HIV/AIDS drug development and interventions. Other topics of interest are cytomegalovirus and herpesvirus research, HIV in relation to drug use and sexual risk, and immune cell function and interaction.

Charles B. Hicks has collaborated frequently with other researchers, including Joseph J. Eron, Guido Ferrari, Cynthia L. Gay, Kara McGee, and Mehri McKellar. These collaborations have contributed to a varied publication record across different academic venues.

The scientist has published extensively in venues such as UNC Libraries, where they have 19 publications. Other publication venues include the Journal of Applied Physiology, Journal of Antimicrobial Chemotherapy, Viruses, and AIDS.

Recent notable papers authored or co-authored by Charles B. Hicks include:

  • A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings, 2023, Viruses
  • Pathogenesis of obstructive sleep apnea in people living with HIV, 2021, Journal of Applied Physiology
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection, 2020, AIDS
  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men, 2020, UNC Libraries
  • Testing for HIV infection in the emergency departments of 2 hospitals in the Southeastern United States, 2020, Journal of the American College of Emergency Physicians Open

Best Publications

  • Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

    Georgia D. Tomaras;Nicole L. Yates;Pinghuang Liu;Li Qin

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

    Olivier Lambotte;Guido Ferrari;Christiane Moog;Nicole L Yates

  • Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

    Schlomo Staszewski;Philip Keiser;Julio Montaner;Francois Raffi

  • Seronegative Secondary Syphilis in a Patient Infected with the Human Immunodeficiency Virus (HIV) with Kaposi Sarcoma: A Diagnostic Dilemma

    Charles B. Hicks;Paul M. Benson;George P. Lupton;Edmund C. Tramont

  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.

    Hui-Hui Li;Katharine J. Bar;Shuyi Wang;Julie M. Decker

  • ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

    Robert L. Murphy;Scott Brun;Charles Hicks;Joseph J. Eron

  • Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

    Marc C. Levesque;M. Anthony Moody;Kwan Ki Hwang;Dawn J. Marshall

  • Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population.

    Christopher D. Pilcher;J. Todd McPherson;Peter A. Leone;Marlene Smurzynski

  • HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.

    Christopher D. Pilcher;Diane C. Shugars;Susan A. Fiscus;William C. Miller

  • Raltegravir: The First HIV Type 1 Integrase Inhibitor

    Charles Hicks;Roy M. Gulick

  • Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

    S. Munir Alam;Richard M. Scearce;Robert J. Parks;Kelly Plonk

  • Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients

    Constance A. Benson;Steven G. Deeks;Scott C. Brun;Roy M. Gulick

  • Late Diagnosis of HIV Infection: The Role of Age and Sex

    Michael J. Mugavero;Chelsea Castellano;David Edelman;David Edelman;Charles Hicks

  • Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

    Charles Hicks;Martin S. King;Roy M. Gulick;A. Clinton White

  • Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1

    Kimberly Ritola;Christopher D. Pilcher;Susan A. Fiscus;Noah G. Hoffman

  • Resistance to HIV Integrase Strand Transfer Inhibitors among Clinical Specimens in the United States, 2009-2012

    Christopher B. Hurt;Joseph Sebastian;Charles B. Hicks;Joseph J. Eron

  • Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections

    S. Gnanakaran;Tanmoy Bhattacharya;Tanmoy Bhattacharya;Marcus Daniels;Brandon F Keele;Brandon F Keele

  • Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons.

    Wanda Lakey;Lan-Yan Yang;William Yancy;Shein-Chung Chow

  • HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.

    Gerald S. Bloomfield;Prateeti Khazanie;Alison Morris;Cristina Rabadán-Diehl

  • Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection: Missed Opportunities in Acute Care Settings

    Amy C. Weintrob;Julieta Giner;Prema Menezes;Ericka Patrick

  • In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth

    Xiaoying Shen;Robert J. Parks;David C. Montefiori;Jennifer L. Kirchherr

Frequent Co-Authors

Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Barton F. Haynes
Barton F. Haynes Duke University
Guido Ferrari
Guido Ferrari Duke University
Susan A. Fiscus
Susan A. Fiscus University of North Carolina at Chapel Hill
Georgia D. Tomaras
Georgia D. Tomaras Duke University
George M. Shaw
George M. Shaw University of Pennsylvania
Kent J. Weinhold
Kent J. Weinhold Duke University
Christopher D. Pilcher
Christopher D. Pilcher University of California, San Francisco
Roy M. Gulick
Roy M. Gulick Cornell University
Constance A. Benson
Constance A. Benson University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology opens the door to a variety of related degree programs and career options. For those interested in public health, exploring easy mph online programs can be a practical step. These programs provide foundational knowledge applicable to microbiology, especially in epidemiology and disease control.

Career pathways linked to microbiology also extend into healthcare specialties. For example, becoming a child life specialist is a rewarding role that supports patients emotionally, with competitive child.life specialist salary prospects. Microbiology graduates can tailor their skills to such patient-centered careers.

It’s important to note that accessible online learning options exist even for individuals with challenging backgrounds. The guide on online degrees for felons highlights programs that support career advancement and social reintegration, emphasizing inclusive education opportunities.

Finally, specialized healthcare roles like functional medicine nurse practitioners combine clinical expertise with holistic approaches. Those interested can explore earning potential through the functional medicine nurse salary resource to understand career viability and growth.

Best Scientists Citing Charles B. Hicks

Trending Scientists

Recently Published Articles